Recombinant human alpha galactosidase A
Alternative Names: GC1119Latest Information Update: 01 Apr 2022
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Carminatives; Enzymes; Recombinant proteins
- Mechanism of Action Alpha glucosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fabry's disease
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 04 Nov 2017 No recent reports of development identified for phase-I development in Fabry's-disease in South Korea (IV, Infusion)
- 26 Jul 2013 Phase-I development is ongoing in South Korea